|
Vertex Pharmaceuticals Inc - Comparative Business Analysis Snapshot
Business Description
Vertex Pharmaceuticals Inc. The Group's principal activity is to discover, develop and market small molecule drugs for the treatment of serious diseases. These drugs used for the treatment of diseases like HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, bacterial infection, pain and other neurological diseases, independently and with collaborators. The Group's telaprevir drug candidate, is an oral hepatitis C protease inhibitor and new class of antiviral treatments in clinical development that target hepatitis C virus or HCV, infection, a life-threatening disease.
Competitor Analysis
This analysis compares Vertex Pharmaceuticals Inc with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
